Breo Ellipta FDA Approved Drugs
BREO ELLIPTA [Fluticasone FuroateC27H29F3O6S : Vilanterol TrifenatateC24H33Cl2NO5C20H16O2]
RX
- 0.1mg/inh : eq 0.025mg base/inh (inhalation powder)
0.2mg/inh : eq 0.025mg base/inh (inhalation powder)
Glaxo Grp LtdMay 10, 2013
- For the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations.
- Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations.
- Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older.
- Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.